Lonza Group Ltd.'s Capsules & Health Ingredients business

Lonza Group Ltd. specializes in the design and manufacturing of hard empty capsules and health ingredients for pharmaceuticals and nutraceuticals, enhancing product delivery systems for health solutions. Lonza Group Ltd. 's Capsules & Health Ingredients business is based in Switzerland and focuses on encapsulation technologies.

It underwent a CORPORATE CARVE OUT on March 6, 2026, when Lone Star Funds acquired it for CHF 1. 7 billion. The company does not have publicly available information about prior pivots or subsidiaries, nor is there any mention of founders or previous companies established by them. The company specializes in the design, manufacturing, and encapsulation of a broad range of hard empty capsules and health ingredients tailored for the pharmaceutical and nutraceutical industries.

Its core product offerings include patented capsule technologies such as Capsugel® Coni-Snap® hard gelatin capsules, which facilitate high-speed filling and secure locking, and Vcaps® Plus HPMC capsules, known for being a premium, non-animal alternative. Additionally, the company provides specialized health ingredients like Carnipure® L-carnitine and UC-II® undenatured type II collagen, aimed at enhancing human and animal nutrition. Their products are strategically marketed to pharmaceutical companies, nutraceutical brands, and food supplement manufacturers across various global markets, including North America, Europe, Asia, and Latin America. The end users include patients, consumers seeking health supplements, and businesses that require reliable delivery systems for their formulations.

The company's revenue is generated through a multifaceted transaction structure that includes B2B partnerships and direct business relationships with clients across the pharmaceutical and nutraceutical sectors. Key transactions typically involve long-term supply agreements and customized contracts with manufacturers of health products. The company’s flagship offerings, such as Capsugel® and its innovative liquid-filled capsules, are integral to its revenue model, as they meet the specific needs of its clients for effective delivery systems. With a focus on comprehensive service provision, including regulatory support and technical assistance, the company fosters ongoing collaborations that enhance customer loyalty and retention.

These partnerships often lead to bulk orders and recurrent business, contributing to the overall financial health of the firm. In March 2026, Lone Star Funds agreed to acquire Lonza Group Ltd. 's Capsules & Health Ingredients business for CHF 1. 7 billion.

This acquisition will support the business's next phase of growth. Future plans include the introduction of new product lines designed to meet the evolving needs of the pharmaceutical and nutraceutical markets. The company is targeting expansion into emerging markets in Asia and Latin America by 2027 to enhance its global footprint. The recent funding will be utilized to accelerate these initiatives, ensuring ample resources for product development and market entry efforts.